Murphy & Mullick Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Murphy & Mullick Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Buy	3,957 +3	+0.1%	+$172	0.14%	129
2026 Q1	$240K	Buy	3,954 +646	+20%	+$37.7K	0.18%	118
2025 Q4	$178K	Sell	3,308 -762	-19%	-$36.7K	0.13%	151
2025 Q3	$184K	Sell	4,070 -865	-18%	-$40.4K	0.14%	147
2025 Q2	$215K	Sell	4,935 -503	-9%	-$24.7K	0.17%	122
2025 Q1	$332K	Buy	5,438 +2	+0%	+$117	0.32%	74
2024 Q4	$307K	Buy	+5,436	New	+$304K	0.28%	84

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Murphy & Mullick Capital Management's BMY Position: Q2 2026 in Review

Murphy & Mullick Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.08% in Q2 2026, buying an estimated $172 and bringing the position to 3,957 shares worth $228K. The position accounts for 0.14% of the portfolio, ranked #129.

Murphy & Mullick Capital Management first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $332K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Murphy & Mullick Capital Management held 3,957 shares of Bristol-Myers Squibb worth $228K as of Q2 2026.
Murphy & Mullick Capital Management bought 3 Bristol-Myers Squibb shares in Q2 2026, an estimated $172.
Bristol-Myers Squibb made up 0.14% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #129 holding.
Murphy & Mullick Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
Murphy & Mullick Capital Management's Bristol-Myers Squibb position peaked at $332K in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.